Patent EP3468587A1 for Cancer Biomarker Detection

ChangeBridge: EPO Bulletin - Peptides (C07K)

Published March 11th, 2026

Detected March 25th, 2026

Summary

The European Patent Office has published patent application EP3468587A1 concerning monoclonal antibodies, compositions, and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer. The patent is assigned to the University of Leicester and Omeros Corporation.

View original document View source feed page

What changed

This document is a publication of a European patent application (EP3468587A1) for a novel method of detecting cancer biomarkers. The patent, assigned to the University of Leicester and Omeros Corporation, focuses on monoclonal antibodies and compositions for identifying mucin-like protein (MLP) as an indicator for ovarian and pancreatic cancers.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in diagnostic tools and therapeutics within the oncology space. Companies involved in cancer diagnostics or treatment may wish to monitor the progress of this patent and related intellectual property.

Source document (simplified)

← EPO Patent Bulletin

MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHODS FOR DETECTING MUCIN -LIKE PROTEIN (MLP) AS A BIOMARKER FOR OVARIAN AND PANCREATIC CANCER

Publication EP3468587A1 Kind: A1 Mar 11, 2026

Applicants

University of Leicester, Omeros Corporation

Inventors

SCHWAEBLE,Hans-Wilhelm, DEMOPULOS, Gregory, A.

IPC Classifications

C07K 16/30 20060101AFI20260204BHEP A61K 39/00 20060101ALI20260204BHEP C12P 21/08 20060101ALI20260204BHEP C12N 15/02 20060101ALI20260204BHEP G01N 33/53 20060101ALI20260204BHEP C07K 14/47 20060101ALI20260204BHEP A61P 35/00 20060101ALI20260204BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →